Biolase, Inc. short interest in 2020
In 2020, Biolase, Inc.'s disclosed short interest ran from 1.62% of shares outstanding on 15 Jan 2020 to 2.06% on 15 Dec 2020, a change of +0.44 percentage points. The year's high was 2.38% on 15 Apr 2020 and its low 0.30% on 15 Oct 2020, averaging 1.14% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.37 days on 31 Mar 2020. Full history: Biolase, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023
2020 in figures
- Start of year
- 1.62% (15 Jan 2020)
- End of year
- 2.06% (15 Dec 2020)
- Change
- +0.44 pp
- High
- 2.38% (15 Apr 2020)
- Low
- 0.30% (15 Oct 2020)
- Average
- 1.14%
- Highest days to cover
- 4.37 (31 Mar 2020)
- SEC filings marked
- 9
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 1.62% | 3.49 | |
| 31 Jan 2020 | 1.07% | 1.63 | |
| 14 Feb 2020 | 0.99% | 1.62 | |
| 28 Feb 2020 | 1.01% | 2.99 | |
| 13 Mar 2020 | 0.95% | 2.61 | |
| 31 Mar 2020 | 1.16% | 4.37 | results (8-K), 10-K filed |
| 15 Apr 2020 | 2.38% | 1.00 | |
| 30 Apr 2020 | 1.05% | 1.00 | |
| 15 May 2020 | 1.20% | 1.00 | results (8-K), 10-Q filed |
| 29 May 2020 | 1.02% | 1.00 | |
| 30 Jun 2020 | 2.26% | 1.00 | |
| 31 Jul 2020 | 1.95% | 1.00 | |
| 14 Aug 2020 | 0.92% | 1.00 | results (8-K), 10-Q filed |
| 31 Aug 2020 | 0.56% | 1.00 | |
| 15 Sep 2020 | 0.56% | 1.00 | |
| 30 Sep 2020 | 0.36% | 1.00 | |
| 15 Oct 2020 | 0.30% | 1.00 | results (8-K) |
| 30 Oct 2020 | 0.54% | 1.00 | |
| 13 Nov 2020 | 0.98% | 1.00 | results (8-K), 10-Q filed |
| 30 Nov 2020 | 1.04% | 1.00 | |
| 15 Dec 2020 | 2.06% | 1.00 |
See also: Biolase, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.